Robert Eldon Brown

← Back to Imperial College London

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. Whole–genome characterization of chemoresistant ovarian cancer

   2015 · 1,569 citations

2. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

   2008 · 1,467 citations

3. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

   2018 · 912 citations

4. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

   2013 · 528 citations

5. DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies

   2005 · 510 citations

6. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter

   2000 · 486 citations

7. Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking

   2012 · 396 citations

8. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer

   2015 · 356 citations

9. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

   2013 · 351 citations

10. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

    1999 · 350 citations

11. The Creation of the American Republic, 1776-1787

    1970 · 339 citations

12. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity.

    1994 · 327 citations

13. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

    2003 · 311 citations

14. Poised epigenetic states and acquired drug resistance in cancer

    2014 · 300 citations

15. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

    2018 · 296 citations

16. Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line

    1996 · 295 citations

17. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis

    2019 · 288 citations

18. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling

    2012 · 285 citations

19. The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients

    2004 · 262 citations

20. CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer

    2005 · 256 citations

21. Common variants at 19p13 are associated with susceptibility to ovarian cancer

    2010 · 246 citations

22. A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

    2008 · 244 citations

23. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

    1997 · 243 citations

24. Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer

    2007 · 238 citations

25. Epigenetics as a mechanism driving polygenic clinical drug resistance

    2006 · 237 citations

← Return to the university profile